Serum HMGB1 is overexpressed in new-onset PM/DM patients with ILD; patients with higher serum HMGB1 levels have lower overall survival, whereas those with lower serum HMGB1 levels have higher overall survival (82). Here, HMGB1 is linked to polymyositis.